Professional Documents
Culture Documents
US Antidiabetics Drug Market Outlook 2022 report gives clinical & non-clinical insight on
trends associated with the development of Antidiabetics drug market in US. Report helps to
identify the diabetes epidemiology (Prevalence of Type 1 & 2 Diabetes) in the US market
along with the associated economic burden & productivity loss.
Diabetes rates in the US have been increasing substantially. While the number of people with
diabetes in the US continues to grow, the number of new cases has been declining since 2009,
after decades of increases in new cases. Although the numbers are not growing dramatically
each year, they are still alarmingly high. About 8.1 Million people with diabetes do not have
knowledge that they have diabetes as prediabetes & type2 diabetes have few physical
symptoms.
Diabetes mellitus being the most common chronic disease with high mortality, morbidity &
costs, the number of people with diabetes is still increasing in US & other countries. More
than 29 million Americans are living with diabetes, & 86 million are living with prediabetes.
Though the benefits of tight control of blood glucose have been well recognized still the
management of diabetes is complex which dem&s for the more efficient st&ardized
antidiabetic regimen.
US insulin market occupies more than 70% of the overall insulin market & is expected to grow
significantly until 2022 owing to the growing number of individuals with diabetes. Factors
such as better accessibility to treatment therapies & favorable reimbursement programs will
result in the high turnout of patients opting for diabetes treatment, which in turn will boost
the markets growth prospects in this region.
The US Antidiabetics Drug Market has seen a resurgence of activity in recent years with
promising new products, such as ultra-rapid-acting & liver targeted insulin analogues, &
insulin plus GLP-1 combinations in late stage development. Earlier stage c&idates include
several oral formulations, as well as ultra-long acting insulin analogues. Some ultra-long
acting insulin analogues in development have the potential to greatly reduce the dosing
frequency to just once weekly for basal insulin needs, as opposed to once daily.
In addition, the prospect of promising drugs in the pipeline, along with increasing awareness,
is expected to contribute to the market's growth during the forecast period. The market is
Table of Contents
4.1.1 Biguanides
4.1.3 Sulfonylureas
4.1.4 Meglitinides
US Diabetes Epidemiology
6.2 Economic Burden Associated with Type 1 & 2 Diabetes: Productivity Loss & Medical Bills
Competitive L&scape
12.1 AstraZeneca
12.2 Bayer
12.4 Eli-Lilly
12.6 Merck
12.7 Novartis
12.9 Sanofi
12.10 Takeda
Figure 6-1: US: Number of Type 1 Diabetes Incidence (Million), 2016 & 2022
Figure 6-2: US: Number of Type 2 Diabetes Incidence (Million), 2014 - 2022
Figure 6-3: US: Type 1 Diabetes Prevalence Rate (%), 2016 & 2022
Figure 6-4: US: Type 2 Diabetes Prevalence Rate (%), 2014 - 2022
Figure 6-5: US: Diabetes Prevalence Rate among Adults Aged 18+ (%), 2010 - 2016
Figure 6-6: US: Obesity Rate Among Adults Aged 18+ (%), 2010 - 2016
Figure 6-7: US: Percentage of Adults with Obesity by State (%), 2015
Figure 6-10: US: Productivity Loss Due To Type 1 Diabetes (US$ Billion), 2014 - 2022
Figure 6-12: US: Medical Cost for Type 1 Diabetes (US$ Billion), 2014-2022
Figure 6-13: US: Medical Cost for Type 2 Diabetes (US$ Billion), 2014-2022
Figure 7-2: US: Antidiabetics Drug Market (US$ Billion), 2014 - 2022
Figure 7-3: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion),
2016
Figure 8-1: US - Insulin Degludec (Tresiba) Injection Sales (US$ Million), 2016-2022
Figure 8-3: US - Insulin Glargine (Toujeo) Injection Sales (US$ Million), 2016-2022
Figure 8-4: US - Insulin Glulisine (Apidra) Injection Sales (US$ Million), 2016-2022
Figure 8-5: US - Insulin Detemir (Levemir FlexTouch) Injection Sales (US$ Million), 2016-2022
Figure 10-3: Estimated Increase in Total Number with Diagnosed Diabetes till 2050
Figure 11-1: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$
Billion), 2022